LRRK2 Antikörper (AA 931-962)

Produktnummer ABIN1882109

Produktdetails anti-LRRK2 Antikörper

Target: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Bindungsspezifität: AA 931-962

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser LRRK2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Aufreinigung: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 931-962 amino acids from human PARK8(LRRK2).

Klon: RB7199

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Haltbarkeit: 6 months

Referenzen für anti-LRRK2 Antikörper (ABIN1882109)

Biskup, Moore, Rea, Lorenz-Deperieux, Coombes, Dawson, Dawson, West: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." in: BMC neuroscience, Vol. 8, pp. 102, (2008) (PubMed).

Shen: "Protein kinases linked to the pathogenesis of Parkinson's disease." in: Neuron, Vol. 44, Issue 4, pp. 575-7, (2004) (PubMed).

Wszolek, Pfeiffer, Tsuboi, Uitti, McComb, Stoessl, Strongosky, Zimprich, Müller-Myhsok, Farrer, Gasser, Calne, Dickson: "Autosomal dominant parkinsonism associated with variable synuclein and tau pathology." in: Neurology, Vol. 62, Issue 9, pp. 1619-22, (2004) (PubMed).

Zimprich, Biskup, Leitner, Lichtner, Farrer, Lincoln, Kachergus, Hulihan, Uitti, Calne, Stoessl, Pfeiffer, Patenge, Carbajal, Vieregge, Asmus, Müller-Myhsok, Dickson, Meitinger, Strom, Wszolek, Gasser: "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology." in: Neuron, Vol. 44, Issue 4, pp. 601-7, (2004) (PubMed).

Details zu LRRK2

Target: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Andere Bezeichnung: PARK8 (LRRK2) (LRRK2 Produkte)

Synonyme: LRRK2 antikoerper, AURA17 antikoerper, DARDARIN antikoerper, PARK8 antikoerper, RIPK7 antikoerper, ROCO2 antikoerper, 4921513O20Rik antikoerper, 9330188B09Rik antikoerper, AW561911 antikoerper, D630001M17Rik antikoerper, Gm927 antikoerper, cI-46 antikoerper, leucine-rich repeat kinase 2 antikoerper, leucine rich repeat kinase 2 antikoerper, lrrk2 antikoerper, LRRK2 antikoerper, Lrrk2 antikoerper

Hintergrund: Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

Molekulargewicht: 286103

NCBI Accession: NP_940980

UniProt: Q5S007

Pathways: Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development